Identification of cytochrome P450s involved in the metabolism of 6-benzyl-1-benzyloxymethyl-5-iodouracil (W-1) using human recombinant enzymes and rat liver microsomes in vitro

References

• Bi Y, Zhuang X, Zhu H, et al. (2015). Studies on metabolites and metabolic pathways of bulleyaconitine A in rat liver microsomes using LC-MS(n) combined with specific inhibitors. Biomed Chromatogr 29:1027–34.
   PubMed Web of Science ®Google Scholar
• Buckheit RW Jr, Watson Buckheit K, Sturdevant CB, Buckheit RW, III (2013). Selection and characterization of viruses resistant to the dual acting pyrimidinedione entry and non-nucleoside reverse transcriptase inhibitor IQP-0410. Antiviral Res 100:382–91.
   PubMed Web of Science ®Google Scholar
• Campiani G, Ramunno A, Maga G, et al. (2002). Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Curr Pharm Des 8:615–57.
   PubMed Web of Science ®Google Scholar
• Chen L, Cai J, Wang S, et al. (2015). Effect of radix sophorae flavescentis on activity of CYP450 isoforms in rats. Int J Clin Exp Med 8:21365–71.
   PubMed Web of Science ®Google Scholar
• Cooke CE, Lee HY, Xing S. (2014). Adherence to antiretroviral therapy in managed care members in the United States: a retrospective claims analysis. J Manag Care Pharm 20:86–92.
   PubMed Web of Science ®Google Scholar
• Feng M, Wang D, Grobler JA, et al. (2015). In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother 59:590–8.
   PubMed Web of Science ®Google Scholar
• Feng R, Zhou X, Tan XS, et al. (2014). In vitro identification of cytochrome P450 isoforms responsible for the metabolism of 1-hydroxyl-2,3,5-trimethoxy-xanthone purified from Halenia elliptica D. Don. Chem Biol Interact 210:12–19.
   PubMed Web of Science ®Google Scholar
• Foti RS, Rock DA, Wienkers LC, Wahlstrom JL. (2010). Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos 38:981–7.
   PubMed Web of Science ®Google Scholar
• Griffin L, Annaert P, Brouwer KL. (2011). Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J Pharm Sci 100:3636–54.
   PubMed Web of Science ®Google Scholar
• Guo W, Shi X, Wang W, et al. (2014). Identification of the rat liver cytochrome P450 enzymes involved in the metabolism of the calcium channel blocker dipfluzine hydrochloride. Environ Toxicol Pharmacol 38:901–12.
   PubMed Web of Science ®Google Scholar
• Ioannides C. (2013). Up-regulation of cytochrome P450 and phase II enzymes by xenobiotics in precision-cut tissue slices. Xenobiotica 43:15–28.
   PubMed Web of Science ®Google Scholar
• Jonckheere H, Anné J, De Clercq E. (2000). The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med Res Rev 20:129–54.
   PubMed Web of Science ®Google Scholar
• Kirby BJ, Collier AC, Kharasch ED, et al. (2011). Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab Dispos 39:1070–8.
   PubMed Web of Science ®Google Scholar
• Liu H, Ma Y, Su Y, et al. (2014). Emerging trends of HIV drug resistance in Chinese HIV-infected patients receiving first-line highly active antiretroviral therapy: a systematic review and meta-analysis. Clin Infect Dis 59:1495–502.
   PubMed Web of Science ®Google Scholar
• Lu D, Dong D, Liu Z, et al. (2015). Metabolism elucidation of BJ-B11 (a heat shock protein 90 inhibitor) by human liver microsomes: identification of main contributing enzymes. Expert Opin Drug Metab Toxicol 11:1029–40.
   PubMed Web of Science ®Google Scholar
• Lu YY, Wang X, Wang XW, et al. (2015). Development and validation of a high performance liquid chromatography method for determination of 6-benzyl-1-benzyloxymethyl-5-iodouracil (W-1), a novel non-nucleoside reverse transcriptase inhibitor and its application to a pharmacokinetic study in rats. Biomed Chromatogr 29:1548–52.
   PubMed Web of Science ®Google Scholar
• Lu YY, Wang XW, Wang X, et al. (2016). Profile of disposition, tissue distribution and excretion of the novel anti-human immunodeficiency virus (HIV) agent W-1 in rats. Arch Pharm Res 39:970–7.
   PubMed Web of Science ®Google Scholar
• Mannu J, Jenardhanan P, Mathur PP. (2011). A computational study of CYP3A4 mediated drug interaction profiles for anti-HIV drugs. J Mol Model 17:1847–54.
   PubMed Web of Science ®Google Scholar
• Melikian GL, Rhee SY, Varghese V, et al. (2014). Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob Chemother 69:12–20.
   PubMed Web of Science ®Google Scholar
• Ning J, Hou J, Wang P, et al. (2015). Interspecies variation in phase I metabolism of bufalin in hepatic microsomes from mouse, rat, dog, minipig, monkey, and human. Xenobiotica 45:954–60.
   PubMed Web of Science ®Google Scholar
• Preissner SC, Hoffmann MF, Preissner R, et al. (2013). Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One 8:e82562.
   PubMed Web of Science ®Google Scholar
• Qin H, Liu C, Guo Y, et al. (2010). Synthesis and biological evaluation of novel C5 halogen-functionalized S-DABO as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem 18:3231–7.
   PubMed Web of Science ®Google Scholar
• Reynolds C, de Koning CB, Pelly SC, et al. (2012). In search of a treatment for HIV-current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs). Chem Soc Rev 41:4657–70.
   PubMed Web of Science ®Google Scholar
• Scott SA, Sangkuhl K, Gardner EE, et al. (2011). Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 90:328–32.
   PubMed Web of Science ®Google Scholar
• Shibano M, Lin AS, Itokawa H, Lee KH. (2007). Separation and characterization of active flavonolignans of Silybum marianum by liquid chromatography connected with hybrid ion-trap and time-of-flight mass spectrometry (LC-MS/IT-TOF). J Nat Prod 70:1424–8.
   PubMed Web of Science ®Google Scholar
• Tran JQ, Gerber JG, Kerr BM. (2001). Delavirdine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 40:207–26.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang J, Huang Y, et al. (2012). Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile. J Med Chem 55:2242–50.
   PubMed Web of Science ®Google Scholar
• Ward BA, Gorski JC, Jones DR, et al. (2003). The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287–300.
   PubMed Web of Science ®Google Scholar
• Wu Q, Huang L, Liu Z, et al. (2011). A comparison of hepatic in vitro metabolism of T-2 toxin in rats, pigs, chickens, and carp. Xenobiotica 41:863–73.
   PubMed Web of Science ®Google Scholar
• Xu C, Desta Z. (2013). In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. Drug Metab Pharmacokinet 28:362–71.
   PubMed Web of Science ®Google Scholar
• Yamamura Y, Koyama N, Umehara K. (2015). Comprehensive kinetic analysis and influence of reaction components for chlorzoxazone 6-hydroxylation in human liver microsomes with CYP antibodies. Xenobiotica 45:353–60.
   PubMed Web of Science ®Google Scholar
• Yanakakis LJ, Bumpus NN. (2012). Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos 40:803–14.
   PubMed Web of Science ®Google Scholar
• Yu Y, Liu Z, Ju P, et al. (2013). In vitro metabolism of alisol A and its metabolites' identification using high-performance liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 941:31–7.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–41.
   PubMed Web of Science ®Google Scholar
• Zhan P, Chen X, Li D, et al. (2013). HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design. Med Res Rev 33:E1–72.
   PubMed Web of Science ®Google Scholar
• Zhang YZ, Xu F, Dong J, et al. (2012). Profiling and identification of the metabolites of calycosin in rat hepatic 9000 × g supernatant incubation system and the metabolites of calycosin-7-O-β-D-glucoside in rat urine by HPLC-DAD-ESI-IT-TOF-MS(n) technique. J Pharm Biomed Anal 70:425–39.
   PubMed Web of Science ®Google Scholar
• Zhuang XM, Deng JT, Li H, et al. (2011). Metabolism of novel anti-HIV agent 3-cyanomethyl-4-methyl-DCK by human liver microsomes and recombinant CYP enzymes. Acta Pharmacol Sin 32:1276–84.
   PubMed Web of Science ®Google Scholar